{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-011514","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.001374+00:00","generated_at":"2026-06-16T06:41:24.535550+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SAB Biotherapeutics reports positive Phase 3 results for SAB-185 in high-risk COVID-19 patients","bullets":["66% of SAB-185 patients reached sustained symptom resolution by Day 28 vs 50% for REGEN-COV (p=0.010).","Median time to symptom resolution was 7 days shorter for SAB-185 vs REGEN-COV (p=0.010).","Primary endpoint (hospitalization/death) inconclusive due to low events after Omicron emergence.","Grade 3+ adverse event rates similar between SAB-185 and REGEN-COV arms.","SAB-176 for influenza granted Fast Track and Breakthrough Therapy designations from FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-011514","json":"https://secwatch.observer/filing/0001437749-23-011514.json","markdown":"https://secwatch.observer/filing/0001437749-23-011514.md","text":"https://secwatch.observer/filing/0001437749-23-011514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923011514/0001437749-23-011514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923011514/sabs20230427_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:41:24.535550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}